Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Apollomics Inc. Warrant (APLMW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/18/2025: APLMW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/18/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 122.66M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 0.03 - 0.03 | Updated Date 06/28/2025 |
52 Weeks Range 0.03 - 0.03 | Updated Date 06/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 20542439 | Price to Sales(TTM) - |
Enterprise Value 20542439 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.12 | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Apollomics Inc. Warrant
Company Overview
History and Background
Apollomics Inc. was a biopharmaceutical company focused on the discovery, development, and commercialization of immuno-oncology and targeted therapies to treat cancer. The warrants were associated with a SPAC merger. Apollomics announced its dissolution in November 2023.
Core Business Areas
- Drug Development: Focused on the discovery, development, and commercialization of cancer therapies.
Leadership and Structure
Historically, Apollomics Inc. had a CEO and a board of directors. The exact structure is now defunct due to dissolution.
Top Products and Market Share
Key Offerings
- APL-106: A potential drug candidate for cancer treatment. No significant market share data available as it was still in development. Competitors: Numerous established pharmaceutical companies.
- APL-102: Another potential drug candidate for cancer treatment. No significant market share data available as it was still in development. Competitors: Numerous established pharmaceutical companies.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, long development timelines, and intense competition.
Positioning
Apollomics Inc. was a smaller player trying to develop novel cancer therapies. The dissolution ended their competitive positioning.
Total Addressable Market (TAM)
The TAM for cancer therapeutics is very large (hundreds of billions of dollars globally). Apollomics Inc. was positioned to capture a small percentage of this TAM, if successful with its drug candidates. Dissolution eliminated the TAM opportunity.
Upturn SWOT Analysis
Strengths
- Novel drug candidates
- Experienced management team (historically)
Weaknesses
- Limited funding
- High risk of drug development failure
- Small scale compared to major pharmaceutical companies
Opportunities
- Partnerships with larger pharmaceutical companies
- Successful clinical trial results
- Breakthrough therapy designation
Threats
- Failure of clinical trials
- Competition from established therapies
- Regulatory hurdles
- Lack of funding
Competitors and Market Share
Key Competitors
- MRK
- PFE
- BMY
- AMGN
Competitive Landscape
Apollomics Inc. was at a significant disadvantage compared to its competitors due to its smaller size and limited resources.
Growth Trajectory and Initiatives
Historical Growth: No significant historical growth due to the company's stage and eventual dissolution.
Future Projections: No future projections as the company no longer exists.
Recent Initiatives: N/A due to dissolution.
Summary
Apollomics Inc. was a high-risk, high-reward biopharmaceutical company that ultimately failed to achieve its goals, leading to its dissolution. It was a small player in a highly competitive industry. The company faced significant challenges, including funding and clinical trial risks. The warrants are now essentially worthless.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company press releases (historical)
- SEC filings (historical)
- Financial news sources
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. The data may be incomplete or inaccurate due to the company's dissolution. Warrants are considered a speculative investment.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Apollomics Inc. Warrant
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-11-26 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 59 | Website |
Full time employees 59 | Website | ||
Apollomics, Inc., a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. Its pipeline consists of various development-stage assets, including novel and humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2016 and is based in Foster City, California with additional locations in Hangzhou and Shanghai, China and Southbank, Australia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.